The U.S. Food and Drug Administration (FDA) approved on February 12, 2026, changes to the prescribing information for six menopause hormone therapy preparations (hormone replacement therapy, HRT). The risk warnings for cardiovascular diseases, breast cancer, and probable dementia were removed from the "boxed warning" – the most prominent safety warning.
The changes follow a comprehensive review of the scientific literature since November 2025. Preparations from all four main categories of systemic and topical hormone therapies for menopausal women are affected: combination therapies (estrogen + progestogen), estrogen-only preparations, progestogen-only preparations (in women with a uterus), and topical vaginal estrogens.
The FDA justifies the decision with the current evidence: Women who start hormone therapy within ten years of menopause onset (usually before age 60) show a reduction in overall mortality and fracture risk in randomized studies. Vasomotor symptoms (hot flashes, night sweats), vaginal dryness, and osteoporosis can be effectively treated with approved HRT preparations. Nevertheless, only about 2 million women aged 46–65 use such therapy – out of approximately 41 million women in this age group in 2020.
The removal of the warnings is intended to provide women and their treating physicians with a fact-based decision-making basis, free from exaggerated risk presentation. The FDA emphasizes that it follows science and corrects outdated or no longer tenable warnings to enable informed decisions.
Objective Assessment of Significance
The decision marks a significant paradigm shift in the assessment of menopausal hormone therapy. For decades, the results of the Women’s Health Initiative (WHI) from 2002 dominated the guidelines, suggesting an increased risk of breast cancer, heart attack, stroke, and dementia with combined estrogen-progestogen therapy. However, newer analyses and long-term data have shown that the risk profile depends heavily on the age at therapy initiation, duration, and type of hormone preparation. Women under 60 or within ten years of menopause generally have a more favorable benefit-risk ratio, especially with estrogen-only preparations.
Removing the boxed warnings from the most prominent warning level signals that the FDA considers the evidence for an overall positive benefit-risk ratio in appropriate patients to be sufficiently robust – at least for the indicated uses (vasomotor symptoms, vulvovaginal atrophy, osteoporosis prevention). This could alleviate underuse, as many women and physicians avoid the therapy due to the earlier warnings.
What remains critical: The boxed warning regarding cardiovascular risks, breast cancer, and dementia has not been removed without replacement, but only from this section. The prescribing information continues to contain detailed risk warnings in the main text. The decision applies only to the six named preparations; other HRT products must be adjusted individually.
Overall, this is an evidence-based step that objectifies the discussion about hormone therapy in menopause and potentially allows more women informed access to effective symptom relief – with a continued need for individual benefit-risk assessment.
